Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1512760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simple and Fail-safe Method to Transform Miniprep Strain K12 Plasmid DNA Into Viable EHA105 Cells for Plant Genetic Transformation.
Bio Protoc
January 2025
Department of Biochemistry, Microbiology and Biotechnology, Kenyatta University, Nairobi, Kenya.
Agrobacterium-mediated gene transformation method is a vital molecular biology technique employed to develop transgenic plants. Plants are genetically engineered to develop disease-free varieties, knock out unsettling traits for crop improvement, or incorporate an antigenic protein to make the plant a green factory for edible vaccines. The method's robustness was validated through successful transformations, demonstrating its effectiveness as a standard approach for researchers working in plant biotechnology.
View Article and Find Full Text PDFSafety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
J Adv Pract Oncol
November 2024
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.
View Article and Find Full Text PDFMonovalent Anti-CD3 Antibodies Effectively Eliminate the TCR-Positive Fraction of TCR-Deleted Allogeneic CAR-T Cells to Prevent GVHD.
Immune Netw
December 2024
Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Korea.
Chimeric antigen receptor-transduced T (CAR-T) cell therapy is an effective cell therapy against advanced hematological tumors. However, the use of autologous T cells limits its timely and universal generation. Allogeneic CAR-T cell therapy may be a good alternative as a ready-to-use therapeutic.
View Article and Find Full Text PDFPlain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma.
Future Oncol
January 2025
cKite, a Gilead Company, Santa Monica, CA, USA.
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15.
J Immunother Cancer
January 2025
Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
The ability of immune cells to expand numerically after infusion distinguishes adoptive immunotherapies from traditional drugs, providing unique therapeutic advantages as well as the potential for unmanageable toxicities. Here, we describe a case of lethal hyperleukocytosis in a patient with neuroblastoma treated on phase 1 clinical trial (NCT03294954) with autologous natural killer T cells (NKTs) expressing a GD2-specific chimeric antigen receptor and cytokine interleukin 15 (GD2-CAR.15).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!